Warning: mkdir(): Permission denied in /data/Websites/newwiki-mpm/fuel/core/classes/log.php on line 122

Warning!

ErrorException [ Warning ]: mkdir(): Permission denied

COREPATH/classes/log.php @ line 122:

121:	
122:	mkdir($filepath, \Config::get('file.chmod.folders', 0777), true);
123:	umask($old);
STK11 - Wiki-MPM

Search Results for: STK11

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel FAM98B family with sequence similarity 98 member B
  • tRNA processing in the nucleus
Novel MADCAM1 mucosal vascular addressin cell adhesion molecule 1
Novel PPP6R1 protein phosphatase 6 regulatory subunit 1
  • COPII-mediated vesicle transport
Novel SH3GL1 SH3 domain containing GRB2 like 1, endophilin A2
  • EGFR downregulation
  • Negative regulation of MET activity
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
Novel ZNF195 zinc finger protein 195
  • Generic Transcription Pathway
ABCB5 ATP binding cassette subfamily B member 5
  • ABC-family proteins mediated transport
  • Biricodar
  • Dofequidar
ADIPOR1 adiponectin receptor 1
  • AMPK inhibits chREBP transcriptional activation activity
  • AMPK inhibits chREBP transcriptional activation activity
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
ALDOB aldolase, fructose-bisphosphate B
  • Hereditary fructose intolerance
  • Glycolysis
  • Gluconeogenesis
  • Fructose catabolism
  • 1,6-Fructose Diphosphate (Linear Form)
  • sn-glycerol 3-phosphate
  • Dihydroxyacetone phosphate
  • Hereditary fructose intolerance; Fructosemia
ANP32B acidic nuclear phosphoprotein 32 family member B
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Alzheimer's disease (AD)
ARAF A-Raf proto-oncogene, serine/threonine kinase
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • ATP
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
ARG2 arginase 2
  • Urea cycle
  • Arginine
  • Ornithine
  • S-2-(Boronoethyl)-L-Cysteine
ARNT aryl hydrocarbon receptor nuclear translocator
  • Regulation of gene expression by Hypoxia-inducible Factor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
ATM ATM serine/threonine kinase
  • DNA Damage/Telomere Stress Induced Senescence
  • Regulation of HSF1-mediated heat shock response
  • Autodegradation of the E3 ubiquitin ligase COP1
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Sensing of DNA Double Strand Breaks
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • G2/M DNA damage checkpoint
  • Stabilization of p53
  • Meiotic recombination
  • Pexophagy
  • Caffeine
  • Ataxia telangiectasia (AT); Louis-Bar syndrome; Boder-Sedgwick syndrome
  • DNA repair defects, including the following six diseases: Ataxia telangiectasia (AT); Ataxia-talangiectasia-like syndrome; Nijmegen syndrome; DNA ligase I deficiency; DNA ligase IV deficiency; Bloom's syndrome
  • Ataxia with ocular apraxia (AOA), including: Ataxia telangiectasia (AT); Ataxia telangiectasia like disorder (ATLD); Ataxia oculomotor apraxia type 1 (AOA1); Ataxia oculomotor apraxia type 2 (AOA2)
  • Chronic lymphocytic leukemia (CLL)
AURKA aurora kinase A
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Regulation of PLK1 Activity at G2/M Transition
  • SUMOylation of DNA replication proteins
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • AURKA Activation by TPX2
  • Interaction between PHLDA1 and AURKA
  • Phosphonothreonine
  • AT9283
  • CYC116
  • Alisertib
  • SNS-314
  • Cenisertib
  • Enzastaurin
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • AKI-001
  • 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
  • 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
  • N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
  • N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
  • 2-(1H-pyrazol-3-yl)-1H-benzimidazole
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • Fostamatinib
  • MLN8054
BCAS3 BCAS3 microtubule associated cell migration factor
BECN1 beclin 1
  • Macroautophagy
  • Ub-specific processing proteases
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Estradiol
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
BRAF B-Raf proto-oncogene, serine/threonine kinase
  • Spry regulation of FGF signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • ARMS-mediated activation
  • Signalling to p38 via RIT and RIN
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • Sorafenib
  • XL281
  • RAF-265
  • PLX-4720
  • N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide
  • (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
  • Vemurafenib
  • Regorafenib
  • Dabrafenib
  • Encorafenib
  • Fostamatinib
  • Ripretinib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Thyroid cancer
  • Malignant melanoma
CAB39 calcium binding protein 39
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • Neutrophil degranulation

Page 1 out of 7 pages